UNIVAC decision support model A universal framework for evaluating vaccine policy options in low- and middle-income countries

Size: px
Start display at page:

Download "UNIVAC decision support model A universal framework for evaluating vaccine policy options in low- and middle-income countries"

Transcription

1 UNIVAC decision support model A universal framework for evaluating vaccine policy options in low- and middle-income countries Andrew Clark, London School of Hygiene and Tropical Medicine

2 Key questions 1. How do you access, navigate and run UNIVAC? 2. How are the UNIVAC inputs used to generate outputs?

3 Key questions 1. How do you access, navigate and run UNIVAC? 2. How are the UNIVAC inputs used to generate outputs?

4 Key questions 1. How do you access, navigate and run UNIVAC? 2. How are the UNIVAC inputs used to generate outputs?

5 Main output (outcome measure) 1. Cost-utility ratio Cost per DALY averted

6 Outputs of UNIVAC 1. Cost-utility ratio Cost per DALY averted 2. Vaccine costs Incremental vaccine costs 3. Healthcare costs Healthcare costs averted 4. Disease events Cases, visits, hosps., deaths, DALYs 5. Adverse events Cases, visits, hosps., deaths, DALYs 6. Benefit-risk ratio e.g. Deaths averted per death caused

7 Without vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by using United Nations Population Division (UNPOP) projections of the number of individuals that will be alive in each single year of age (and single calendar year) as the birth cohort ages

8 BIRTH COHORTS CALENDAR YEARS

9 BIRTH COHORTS Population, no vaccine CALENDAR YEARS etc... Years of age 9

10 Without vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by using United Nations Population Division (UNPOP) projections of the number of individuals that will be alive in each single year of age (and single calendar year) as the birth cohort ages Multiply by age-specific rates of disease per 100,000 per year to estimate numbers of disease events

11 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS etc... Years of age 11

12 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Years of age For simplicity, this example focuses on disease in under-fives 12

13 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Years of age 13

14 Without vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by using United Nations Population Division (UNPOP) projections of the number of individuals that will be alive in each single year of age (and single calendar year) as the birth cohort ages Multiply by age-specific rates of disease per 100,000 per year to estimate numbers of disease events If you want to account for changes in inputs over time (e.g. demography, mortality rates, coverage, price) then repeat for up to 30 birth cohorts

15 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Years of age 15

16 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS

17 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS

18 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS

19 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS

20 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS

21 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Also useful if you want to report results by calendar year

22 Without vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by using United Nations Population Division (UNPOP) projections of the number of individuals that will be alive in each single year of age (and single calendar year) as the birth cohort ages Multiply by age-specific rates of disease per 100,000 per year to estimate numbers of disease events If you want to account for changes in inputs over time (e.g. demography, mortality rates, coverage, price) then repeat for up to 30 birth cohorts Repeat for each disease type and outcome

23 Disease type 1 Cases Visits Hosps. Deaths

24 Cases Visits Hosps. Deaths Disease type 1 Disease type 2

25 Cases Visits Hosps. Deaths Disease type 1 Disease type 2 Disease type 3 up to 10 types

26 Example: Rotavirus configuration 1 Cases Visits Hosps. Deaths Any RVGE

27 Example: Rotavirus configuration 2 Cases Visits Hosps. Deaths Any RVGE

28 Example: Rotavirus configuration 3 Cases Visits Hosps. Deaths Any GE

29 Example: Rotavirus configuration 4 Cases Visits Hosps. Deaths Non-severe RVGE Severe RVGE

30 Example: Rotavirus configuration 5 Cases Visits Hosps. Deaths Non-severe RVGE Severe RVGE Intussusception The background rate of severe adverse events can also be included if required. Users can then enter the relative risk of vaccination compared to this background rate to estimate vaccine-related events.

31 With vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by specifying the period of vaccination

32 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Vaccinate infants born

33 With vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by specifying the period of vaccination Multiply age-specific disease events by: 1 [ (% covered by only 1 dose x efficacy of dose 1) + (% covered by only 2 doses x efficacy of dose 2) + (% covered by only 3 doses x efficacy of dose 3).etc. ]

34 With vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by specifying the period of vaccination Multiply age-specific disease events by: 1 [ (% covered by only 1 dose x efficacy of dose 1) + (% covered by only 2 doses x efficacy of dose 2) + (% covered by only 3 doses x efficacy of dose 3).etc. ] This calculation is applied by year of age 5-99 years and by week of age <5 years. UNIVAC therefore asks for additional inputs <5yrs: Age distribution of disease by week of age <5yrs; Vaccine coverage/timeliness by week of age <5yrs; Vaccine efficacy by time in weeks since dose given.

35 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Vaccinate infants born

36 BIRTH COHORTS Deaths, routine vaccine CALENDAR YEARS Vaccinate infants born

37 BIRTH COHORTS Deaths, routine vaccine CALENDAR YEARS Vaccinate infants born - and track future benefits

38 COMPARATOR deaths without vaccine NEW OPTION 590 deaths with vaccine e.g. ~50000 future deaths prevented if all children born - are tracked over their lifetimes

39 UNIVAC advantages and drawbacks Advantages Accessibility developed in Excel so familiar to most users; Transparency can be easily explained to national teams and decision makers; Simplicity uses a minimal set of inputs and steps; Flexibility can be quickly adapted to evaluate new options in a timely way; Comparability allows for more standardised comparisons between vaccine policy options; Drawback Static unlike dynamic models, UNIVAC does NOT track the number of susceptible, infectious and immune individuals over time, so cannot directly simulate herd (and other indirect) effects. However, in mitigation (!), calibration of dynamic models: can be a lengthy/complex process; may not provide estimates defensible by MoH if based on poor quality data; may not be necessary if plausible whatif scenarios can demonstrate that inclusion of indirect effects would not change the recommendation/decision.

40 If you want to know more about The PAHO/WHO Provac Initiative The Provac Toolkit Partners

Overview of the ProVac Initiative

Overview of the ProVac Initiative Overview of the ProVac Initiative Updated Dec. 2017 Goal of the ProVac Initiative Strengthen evidence-based decision making on immunization to sustain and further the public health impact of immunization

More information

Papillomavirus Rapid Interface for Modelling and Economics Tool. User Manual

Papillomavirus Rapid Interface for Modelling and Economics Tool. User Manual Papillomavirus Rapid Interface for Modelling and Economics Tool User Manual List of abbreviations DALYs disability adjusted life years GDP HPV IARC gross domestic product human papillomavirus International

More information

Vaccine 31S (2013) C19 C29. Contents lists available at SciVerse ScienceDirect. Vaccine. jou rn al hom ep age: e/vaccine

Vaccine 31S (2013) C19 C29. Contents lists available at SciVerse ScienceDirect. Vaccine. jou rn al hom ep age:   e/vaccine Vaccine 31S (2013) C19 C29 Contents lists available at SciVerse ScienceDirect Vaccine jou rn al hom ep age: wwwelseviercom/locat e/vaccine Review TRIVAC decision-support model for evaluating the cost-effectiveness

More information

Taking vaccine effectiveness into public health decision making: The ProVac Example

Taking vaccine effectiveness into public health decision making: The ProVac Example http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz

More information

Critical immunity thresholds for measles elimination

Critical immunity thresholds for measles elimination Critical immunity thresholds for measles elimination Sebastian Funk Centre for the Mathematical Modelling of Infectious Diseases London School of Hygiene & Tropical Medicine 19 October, 2017!"vöå"!(}å!öZ&!

More information

Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative

Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative http://www.paho.org/provac Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative Cara Bess Janusz Immunization, PAHO 1 st Regional Dengue Symposium 3-4 November

More information

IMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION

IMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION IMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION Marc Brisson Full Professor Université Laval, Canada SAGE meeting October 24, 2018 Geneva 1 Questions A. What is the potential

More information

Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination

Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination Carlo GIAQUINTO Pediatrics Department University of Padova, Italy Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination Preliminary results 7th International Rotavirus

More information

Cost-effectiveness of Influenza Vaccine

Cost-effectiveness of Influenza Vaccine Cost-effectiveness of Influenza Vaccine Lisa A. Prosser, PhD, MS Associate Professor University of Michigan National Influenza Vaccine Summit May 16, 2012 Acknowledgments Funding for this research project

More information

Using a mathematical model to evaluate the impact of different PCV schedules:

Using a mathematical model to evaluate the impact of different PCV schedules: Using a mathematical model to evaluate the impact of different PCV schedules: Preliminary results from the West Africa epidemiological scenario Alessia Melegaro 1, Albert Jan van Hoek 2, Yoon Choi 2, Nigel

More information

Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C

Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C Record Status This is a critical abstract of an economic evaluation that meets the criteria for

More information

Economic Evaluation. Introduction to Economic Evaluation

Economic Evaluation. Introduction to Economic Evaluation Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of

More information

Measles Strategic Planning Tool: Analysis of MCV strategies in developing countries. Emily Simons 29 January 2009

Measles Strategic Planning Tool: Analysis of MCV strategies in developing countries. Emily Simons 29 January 2009 Measles Strategic Planning Tool: Analysis of MCV strategies in developing countries Emily Simons 29 January 2009 Overview The MSP tool Results by question For Indian states: what is best strategy to accelerate

More information

3. Title Vaccination and immunisation data return collected through the COVER

3. Title Vaccination and immunisation data return collected through the COVER 1. Record Type? 2. Unique Number Reassessment R00019 3. Title Vaccination and immunisation data return collected through the COVER 4. Collection Type National 5. Other Reference 6. Description Cover of

More information

Mark Jit 1,2 1. Improving health worldwide. London School of Hygiene & Tropical Medicine 2. Modelling and Economics Unit, Public Health England

Mark Jit 1,2 1. Improving health worldwide. London School of Hygiene & Tropical Medicine 2. Modelling and Economics Unit, Public Health England Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, Geneva, 17-18 April 2018 Full public health value proposition of vaccines (FPHVPs) Global economic investment case for vaccines

More information

Using A Transmission Dynamic Model Of Rotavirus Infection To Determine The Cost- Effectiveness Of Rotavirus Vaccination In Bangladesh

Using A Transmission Dynamic Model Of Rotavirus Infection To Determine The Cost- Effectiveness Of Rotavirus Vaccination In Bangladesh Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Public Health Theses School of Public Health January 2015 Using A Transmission Dynamic Model Of Rotavirus Infection To Determine

More information

Summary of WHO Position on Rotavirus. Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India)

Summary of WHO Position on Rotavirus. Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India) Summary of WHO Position on Rotavirus Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India) Presentation WHO Position Papers on Rotavirus Optimizing immunization

More information

Health technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were:

Health technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were: Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease De Wals P, Nguyen V H, Erickson L J, Guay M, Drapeau J, St-Laurent J Record Status This is a critical

More information

Rift Valley fever in Kenyan pastoral livestock: Individual-based demographic model to analyse the impact of Rift Valley fever

Rift Valley fever in Kenyan pastoral livestock: Individual-based demographic model to analyse the impact of Rift Valley fever Rift Valley fever in Kenyan pastoral livestock: Individual-based demographic model to analyse the impact of Rift Valley fever S. Fuhrimann 1,2, T. Kimani 3,4, F. Hansen 3, B. Bett 3, J. Zinsstag 1,2, E.

More information

Vaccine 26S (2008) F3 F15. Contents lists available at ScienceDirect. Vaccine. journal homepage:

Vaccine 26S (2008) F3 F15. Contents lists available at ScienceDirect. Vaccine. journal homepage: Vaccine 26S (2008) F3 F15 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Review Evolution of the health economics of cervical cancer vaccination Nicole

More information

Introduction to the ProVac Initiative

Introduction to the ProVac Initiative Introduction to the ProVac Initiative E-toolkit training module Nathalie El Omeiri, PAHO/WHO, Washington D.C. Family, Health Promotion and Life Course, Immunization unit, elomeirin@paho.org Contents of

More information

e-bug: Vaccinations Teacher Sheet Student worksheet 1 answers

e-bug: Vaccinations Teacher Sheet Student worksheet 1 answers Student worksheet 1 answers 1. The table below provides the percentage of children immunised by their second birthday against measles, mumps and rubella (MMR) between 1996 and 2014 (England only). This

More information

USING MATHEMATICAL MODELING FOR POLICY AND STRATEGIC PLANNING A case study of VMMC Scale-Up in Eastern and Southern Africa

USING MATHEMATICAL MODELING FOR POLICY AND STRATEGIC PLANNING A case study of VMMC Scale-Up in Eastern and Southern Africa USING MATHEMATICAL MODELING FOR POLICY AND STRATEGIC PLANNING A case study of VMMC Scale-Up in Eastern and Southern Africa INTEREST 2018 Kigali, Rwanda Emmanuel Njeuhmeli, MD, MPH, MBA Senior Medical Advisor

More information

Cost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada

Cost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada Cost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada Derek Weycker, Ph.D. 1 Mark Atwood, M.S. 1 Thomas E. Delea, M.S.I.A. 1 Anoush Youssoufian, B.A. 1 Dion

More information

Gender (in)equality in Human Papilloma Virus (HPV) vaccinations and treatment Prof. Giampiero Favato

Gender (in)equality in Human Papilloma Virus (HPV) vaccinations and treatment Prof. Giampiero Favato Gender (in)equality in Human Papilloma Virus (HPV) vaccinations and treatment Prof. Giampiero Favato Institute of Leadership and Management in Health (ILMH) Kingston University London 1 HPV virus: a gender

More information

Reporting and Interpreting Results of Economic Evaluation

Reporting and Interpreting Results of Economic Evaluation Reporting and Interpreting Results of Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of

More information

Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M

Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Challenges of use of cholera vaccines in Haiti and the Americas

Challenges of use of cholera vaccines in Haiti and the Americas http://www.paho.org Challenges of use of cholera vaccines in Haiti and the Americas Dr. Cuauhtémoc Ruiz Matus Comprehensive Family Immunization Program Background Topics Consultations at PAHO Challenges

More information

Modeling the public health impact of malaria vaccines for developers and policymakers

Modeling the public health impact of malaria vaccines for developers and policymakers Nunes et al. BMC Infectious Diseases 2013, 13:295 RESEARCH ARTICLE Modeling the public health impact of malaria vaccines for developers and policymakers Julia K Nunes 1,9*, Vicky Cárdenas 1,2, Christian

More information

Data inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov

Data inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov Data inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov Vaccine & Infectious Disease Division Fred Hutchinson Cancer Research Center Dynamic model integration The

More information

The cost-effectiveness of vaccination against Lyme disease Shadick N A, Liang M H, Phillips C B, Fossel K, Kuntz K M

The cost-effectiveness of vaccination against Lyme disease Shadick N A, Liang M H, Phillips C B, Fossel K, Kuntz K M The cost-effectiveness of vaccination against Lyme disease Shadick N A, Liang M H, Phillips C B, Fossel K, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Sustaining Immunization in Developing Countries: The Future We Make

Sustaining Immunization in Developing Countries: The Future We Make Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication

More information

Impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries

Impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries August 29, 2018 Impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries Thirteenth International Rotavirus Symposium 29 31 August 2018 Minsk, Belarus Frédéric Debellut Health Economist,

More information

GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:

GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title: GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus Study No.: 111426 (EPI-ROTA-111426) Title: Case-control study to evaluate the effectiveness of GlaxoSmithKline (GSK)

More information

Modelling screening of HPV vaccinated birth cohorts. The infection transmission system

Modelling screening of HPV vaccinated birth cohorts. The infection transmission system Modelling screening of HPV vaccinated birth cohorts Dr. Iacopo Baussano Imperial College, London & UPO/CPO-Piemonte, Italy. The infection transmission system Infectious Agent in case of CC: men in case

More information

Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078

Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078 Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078 Kate M Mitchell, Brooke Hoots, Dobromir Dimitrov, Jason Farley,

More information

Putting it together: The potential role of modeling to explore the impact of FMD

Putting it together: The potential role of modeling to explore the impact of FMD Putting it together: The potential role of modeling to explore the impact of FMD Mo Salman Animal Population Health Institute Colorado State University m.d.salman@colostate.edu And Melissa McLaws European

More information

Infectious Disease Surveillance in NZ. Michael Baker Department of Public Health, University of Otago, Wellington

Infectious Disease Surveillance in NZ. Michael Baker Department of Public Health, University of Otago, Wellington Infectious Disease Surveillance in NZ Michael Baker Department of Public Health, University of Otago, Wellington michael.baker@otago.ac.nz Outline Current best practice High quality surveillance of specific

More information

Economic Evaluation. Defining the Scope of a Costeffectiveness

Economic Evaluation. Defining the Scope of a Costeffectiveness Economic Evaluation Defining the Scope of a Costeffectiveness Analysis II This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes

More information

Stakeholder Dissemination Meeting: Total Systems Effectiveness (TSE) Pilot Project in Thailand

Stakeholder Dissemination Meeting: Total Systems Effectiveness (TSE) Pilot Project in Thailand Stakeholder Dissemination Meeting: Total Systems Effectiveness (TSE) Pilot Project in Thailand Date: Location: Thursday 2 nd August 2018, 9am 12pm Health Intervention and Technology Assessment Program

More information

Reflections on the use of future HIV vaccines as part of an integrated package of preventive measures

Reflections on the use of future HIV vaccines as part of an integrated package of preventive measures Reflections on the use of future HIV vaccines as part of an integrated package of preventive measures Walter Jaoko, KAVI Institute of Clinical Research, University of Nairobi 2016 Global Vaccine & Immunization

More information

Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A

Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Report to the Board. Typhoid vaccines: WHO Position paper. Weekly epidemiological record. 2008; 6: ibid

Report to the Board. Typhoid vaccines: WHO Position paper. Weekly epidemiological record. 2008; 6: ibid Annex B: Background and Overview of Analyses Gavi s Historical Decisions on TCV In the 2008 VIS, the Board prioritised TCVs for Gavi s portfolio along with Rubella, HPV, and JE vaccines. Although no financial

More information

Tuberculosis Tutorials

Tuberculosis Tutorials Tuberculosis Tutorials These tuberculosis (TB) tutorials were created for the EMOD QuickStart v1.8. Later versions of the QuickStart may not be completely compatible with these tutorials as installation

More information

Setting The setting was community. The economic study was carried out in the USA.

Setting The setting was community. The economic study was carried out in the USA. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children Lieu T A, Ray G T, Black S R, Butler J C, Klein J O, Breiman R F, Miller M A, Shinefield H R Record

More information

Value of post-licensure data to assess public health value Example of rotavirus vaccines

Value of post-licensure data to assess public health value Example of rotavirus vaccines Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines

More information

Modelling BCG vaccination in the UK: What is the impact of changing vaccination policy?

Modelling BCG vaccination in the UK: What is the impact of changing vaccination policy? Modelling BCG vaccination in the UK: What is the impact of changing vaccination policy? Sam Abbott Supervisors: Hannah Christensen, Ellen Brooks-Pollock University of Bristol 1 1. Lambert, M. L., Hasker,

More information

The English immunization programme

The English immunization programme The English immunization programme Mary Ramsay Head of Immunisation Public Health England National Health Service Constitution (2009) You have the right to receive the vaccinations that the Joint Committee

More information

Modelling HIV prevention: strengths and limitations of different modelling approaches

Modelling HIV prevention: strengths and limitations of different modelling approaches Modelling HIV prevention: strengths and limitations of different modelling approaches Leigh Johnson Centre for Infectious Disease Epidemiology and Research Background Models of HIV differ greatly in their

More information

WHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI

WHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI WHO Rotavirus Vaccine Update 2012 Dr. Fatima Serhan WHO/FWC/IVB/EPI WHO estimates that 453 000 child deaths occurred during 2008 due to rotavirus infection 41057 32653 39144 98621 82% of these deaths occurred

More information

Setting The setting was primary care. The economic study was carried out in Norway.

Setting The setting was primary care. The economic study was carried out in Norway. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program Wisloff T, Abrahamsen T G, Bergsaker M A, Lovoll O, Moller P, Pedersen M K, Kristiansen

More information

Modelling Innovative Diagnostic Tools for Tuberculosis

Modelling Innovative Diagnostic Tools for Tuberculosis Modelling Innovative Tools for Tuberculosis Ivor Langley Basra Doulla, MoH, Tanzania Hsien-Ho Lin, NTU, Taiwan Kerry Millington Bertie Squire HaCRIC11 - SEPTEMBER 2011 Modelling Innovative Tools for Tuberculosis

More information

Malaria Vaccine Implementation Programme Framework for Policy Decision

Malaria Vaccine Implementation Programme Framework for Policy Decision Malaria Vaccine Implementation Programme Framework for Policy Decision Mary J Hamel, IVR SAGE 17 April 2018 1 Questions for SAGE on the Framework for Policy Decision 1. Does SAGE agree with the approach?

More information

Cost-effectiveness of influenza vaccination in high-risk children in Argentina Dayan G H, Nguyen V H, Debbag R, Gomez R, Wood S C

Cost-effectiveness of influenza vaccination in high-risk children in Argentina Dayan G H, Nguyen V H, Debbag R, Gomez R, Wood S C Cost-effectiveness of influenza vaccination in high-risk children in Argentina Dayan G H, Nguyen V H, Debbag R, Gomez R, Wood S C Record Status This is a critical abstract of an economic evaluation that

More information

Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision. Mary J Hamel, WHO MPAC, 11 April 2018

Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision. Mary J Hamel, WHO MPAC, 11 April 2018 Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision Mary J Hamel, WHO MPAC, 11 April 2018 MVIP update Background to MVIP MVIP Updates Regulatory Vaccine introduction

More information

Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis

Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic

More information

Appendix. Lifetime extrapolation of data from the randomised controlled DiGEM trial

Appendix. Lifetime extrapolation of data from the randomised controlled DiGEM trial Appendix Lifetime extrapolation of data from the randomised controlled DiGEM trial Judit Simon, Alastair Gray, Philip Clarke, Alisha Wade, Andrew Neil, Andrew Farmer on behalf of the Diabetes Glycaemic

More information

Downloaded from:

Downloaded from: Christensen, H; Trotter, CL; Hickman, M; Edmunds, WJ (2014) Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ (Clinical research ed), 349.

More information

EConDA Economics of Chronic Diseases

EConDA Economics of Chronic Diseases EConDA Economics of Chronic Diseases www.econdaproject.eu Funding from the European Union in the framework of the Health Programme Abbygail Jaccard Deputy Director of Public Health Modelling UK Health

More information

Gavi Alliance Strategy : Goal level indicators and disease dashboard

Gavi Alliance Strategy : Goal level indicators and disease dashboard Gavi Alliance Strategy 2016-2020: Goal level indicators and disease dashboard BOARD MEETING Peter Hansen and Hope Johnson 10-11 June 2015, Geneva Reach every child www.gavi.org Strategic enablers Goal-level

More information

Why is surveillance important after introducing vaccines?

Why is surveillance important after introducing vaccines? Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March

More information

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design GSK Medicine: Rotarix (HRV1): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus vaccine Study No.: 114910 (EPI-ROTA-025 VE AU DB) Title: A study on the impact of rotavirus vaccination

More information

Gavi s Vaccine Investment Strategy

Gavi s Vaccine Investment Strategy Gavi s Vaccine Investment Strategy Judith Kallenberg, Head of Policy WHO Product Development for Vaccines Advisory Committee Meeting Geneva, Switzerland, 7-9 September 2015 www.gavi.org Vaccine Investment

More information

Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence

Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence Kate Mitchell, PhD Imperial College London London, UK 14 th June 2016 Introduction: HPTN 078 Enhancing

More information

5 $3 billion per disease

5 $3 billion per disease $3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,

More information

Sun-Young Kim 1,2, Steven Sweet 1, Joshua Chang 1 and Sue J Goldie 1,2* Abstract

Sun-Young Kim 1,2, Steven Sweet 1, Joshua Chang 1 and Sue J Goldie 1,2* Abstract RESEARCH ARTICLE Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden Sun-Young Kim

More information

Economic evaluations of non-traditional vaccinations in middle-income countries Suwantika, Auliya Abdurrohim

Economic evaluations of non-traditional vaccinations in middle-income countries Suwantika, Auliya Abdurrohim University of Groningen Economic evaluations of non-traditional vaccinations in middle-income countries Suwantika, Auliya Abdurrohim IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's

More information

Report to the Board 6-7 June 2018

Report to the Board 6-7 June 2018 6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment

More information

Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model

Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Aggarwal R, Ghoshal U C, Naik S R Record Status This is

More information

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020. Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy

More information

Summary of Definitions of Mission and Strategic Goal Level Indicators. in GAVI Alliance Strategy Updated October 2013

Summary of Definitions of Mission and Strategic Goal Level Indicators. in GAVI Alliance Strategy Updated October 2013 Summary of s of Mission and Strategic Goal Level Indicators in GAVI Alliance Strategy 2011-2015 Updated October 2013 Table of Contents Under five mortality rate ------------------------------------------------------------------------------------------------------------------------

More information

Cost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar

Cost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar CPHA 2009 Cost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar Ismaila AS 1,2, Pereira JA 1, Robson RC 1, Rawson NS 1, Simpson SD 1, Standaert BA 3

More information

What are the outputs? What is generated by whom? Decade of Vaccine Economics (DOVE) 18/07/2014

What are the outputs? What is generated by whom? Decade of Vaccine Economics (DOVE) 18/07/2014 HEALTH IMPACT ESTIMATES & ECONOMIC ANALYSES ARE CRUCIAL TO GLOBAL EFFORTS Decade of Vaccine Economics (DOVE) Costing, Financing and Funding Gap (CFF) Model Presented to IVIR June 17, 2014 Sachi Ozawa,

More information

Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedulevhe_

Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedulevhe_ Volume 12 Number 6 2009 VALUE IN HEALTH Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedulevhe_534 888..898 Richard J. Milne,

More information

A. Green, C. Sortsø, P.B. Jensen, M. Emneus

A. Green, C. Sortsø, P.B. Jensen, M. Emneus A. Green, C. Sortsø, P.B. Jensen, M. Emneus European Diabetes Epidemiology Group EDEG 2015, Chantilly, April 25-27, 2015 The Diabetes Impact Study 2013 uses all available register information on diabetes

More information

Decision-making by the Advisory Committee on Immunization Practices

Decision-making by the Advisory Committee on Immunization Practices Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012

More information

Evaluating Human Papillomavirus (HPV) Vaccination Strategies in Canada using the Cancer Risk Management HPV Microsimulation Model (CRM-HPVMM)

Evaluating Human Papillomavirus (HPV) Vaccination Strategies in Canada using the Cancer Risk Management HPV Microsimulation Model (CRM-HPVMM) Evaluating Human Papillomavirus (HPV) Vaccination Strategies in Canada using the Cancer Risk Management HPV Microsimulation Model (CRM-HPVMM) ARCC Conference Monday, May 27, 2013 Presented by William Flanagan

More information

JTEG s Summary of RTS,S/ AS01 Clinical Trial Data

JTEG s Summary of RTS,S/ AS01 Clinical Trial Data JTEG s Summary of RTS,S/ AS01 Clinical Trial Data Peter Smith On behalf of the Joint Technical Expert Group (JTEG) based on Cohen et al 2010 RTS,S/AS01 Malaria Vaccine l Based on large segment of P. falciparum

More information

Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland

Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Volume 11 Number 5 2008 VALUE IN HEALTH Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Lesley Tilson, BSc (Pharm), PhD, 1 Cara Usher, BSc, PhD, 1 Karina

More information

Immunization Safety Office: Overview and Considerations on Safety of Alternative Immunization Schedules

Immunization Safety Office: Overview and Considerations on Safety of Alternative Immunization Schedules Immunization Safety Office: Overview and Considerations on Safety of Alternative Immunization Schedules Frank DeStefano MD, MPH Immunization Safety Office Division of Healthcare Quality Promotion, National

More information

Health technology The screening of newborns for galactosemia (GAL) using the Beutler test was studied.

Health technology The screening of newborns for galactosemia (GAL) using the Beutler test was studied. Cost-benefit analysis of newborn screening for galactosemia in the Philippines Padilla C D, Dans L F, Estrada S C, Tamondong M R, Laceste J J, Bernal R M Record Status This is a critical abstract of an

More information

THE AFIX PRODUCT TRAINING MANUAL

THE AFIX PRODUCT TRAINING MANUAL THE AFIX PRODUCT TRAINING MANUAL Last Updated: 11/30/2018 Table of Contents The AFIX Product End User Training AFIX Cohort. 4 Provider Selection... 4 Assessment Selection..... 7 Reports.......10 Flexible

More information

Decision Analysis. John M. Inadomi. Decision trees. Background. Key points Decision analysis is used to compare competing

Decision Analysis. John M. Inadomi. Decision trees. Background. Key points Decision analysis is used to compare competing 5 Decision Analysis John M. Inadomi Key points Decision analysis is used to compare competing strategies of management under conditions of uncertainty. Various methods may be employed to construct a decision

More information

Experience with maternal pertussis and PCV13 immunisation in England

Experience with maternal pertussis and PCV13 immunisation in England Experience with maternal pertussis and PCV13 immunisation in England Immunisation, Hepatitis & Blood Safety department Public Health England 5th RIVM Vaccine Preventable Diseases Research day 18 th November

More information

Global reductions in measles mortality and the risk of measles resurgence

Global reductions in measles mortality and the risk of measles resurgence Global reductions in measles mortality 2000 2008 and the risk of measles resurgence Measles is one of the most contagious human diseases. In 1980 before the use of measles vaccine was widespread, there

More information

6IATT Toolkit, Expanding and Simplifying Treatment for Pregnant Women Living with HIV: Managing the Transition to Option B/B+

6IATT Toolkit, Expanding and Simplifying Treatment for Pregnant Women Living with HIV: Managing the Transition to Option B/B+ Costing Tool: Considerations in Costing a Transition to Option B/B+ 6IATT Toolkit, Expanding and Simplifying Treatment for Pregnant Women Living with HIV: Managing the Transition to Option B/B+ www.emtct-iatt.org

More information

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Hornberger J, Robertus K

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Hornberger J, Robertus K Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Hornberger J, Robertus K Record Status This is a critical abstract of an economic evaluation that meets

More information

Schedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE

Schedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE 1 Schedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE Andrew Pollard, SAGE Member SAGE meeting, 18 20 October 2016 Questions for SAGE 2 1. What is the incremental

More information

Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J

Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J Record Status This is a critical abstract of an economic evaluation

More information

Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types

Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development

More information

Economic aspects of viral hepatitis in Turkey. Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009

Economic aspects of viral hepatitis in Turkey. Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009 Economic aspects of viral hepatitis in Turkey Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009 Vaccines currently recommended for children in National Immunization

More information

Cost effectiveness of pertussis vaccination in adults Lee G M, Murphy T V, Lett S, Cortese M M, Kretsinger K, Schauer S, Lieu T A

Cost effectiveness of pertussis vaccination in adults Lee G M, Murphy T V, Lett S, Cortese M M, Kretsinger K, Schauer S, Lieu T A Cost effectiveness of pertussis vaccination in adults Lee G M, Murphy T V, Lett S, Cortese M M, Kretsinger K, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that

More information

Gisele Almeida Public Policies, Regulation, and Health Financing Health Systems and Services

Gisele Almeida Public Policies, Regulation, and Health Financing Health Systems and Services Gisele Almeida Public Policies, Regulation, and Health Financing Health Systems and Services Challenges to the Health Sector External Context Complexity of health determinants Multiplicity of initiatives

More information

Concepts of herd immunity and protection

Concepts of herd immunity and protection Fondation Mérieux Conference Herd Immunity/Protection: an Important Indirect Benefit of Vaccination - Annecy- 26 th October 2010 Concepts of herd immunity and protection Peter Smith London School of Hygiene

More information

Does your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research

Does your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research Does your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research Objectives By the end of the session, participants will be able to: Recognize

More information

Modelling of Infectious Diseases for Prevention and Mitigation: How Modelling has Informed Public Health Policy

Modelling of Infectious Diseases for Prevention and Mitigation: How Modelling has Informed Public Health Policy Modelling of Infectious Diseases for Prevention and Mitigation: How Modelling has Informed Public Health Policy Ruth Chapman, PhD UBC Kamal Desai PhD UBC Deirdre Hollingsworth, PhD Imperial College London

More information

Male Circumcision: Decision Makers Program Planning Tool

Male Circumcision: Decision Makers Program Planning Tool Suggested citation: Bollinger, L., W. DeCormier Plosky, and J. Stover. 2009. Male Circumcision: Decision Makers Program Planning Tool, Calculating the Costs and Impacts of a Male Circumcision Program.

More information

Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination

Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Manish Patel SAGE Geneva 12 April 2012 1 Overview! Update new inputs for benefit risk

More information